Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
N/A
18 Years
75 Years
18 Years
75 Years
Not Enrolling
Both
Myelodysplastic Syndromes, Myeloproliferative Disorders, Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD)
Both
Myelodysplastic Syndromes, Myeloproliferative Disorders, Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD)
Trial Information
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of
Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
Inclusion Criteria:
- Myelodysplastic Syndromes- Myeloproliferative Disorders
- HLA matched donor available
Exclusion Criteria:- organ dysfunction
- HIV positive
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Efficacy of transplant
Outcome Time Frame:
1 year
Safety Issue:
No
Principal Investigator
Ginna Laport
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
BMT128
NCT ID:
NCT00186576
Start Date:
December 2001
Completion Date:
July 2010
Related Keywords:
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Blood and Marrow Transplant (BMT)
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Disorders (MPD)
- Myelodysplastic Syndromes
- Preleukemia
- Myeloproliferative Disorders
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
